Insider Selling: Intercept Pharmaceuticals Inc. (ICPT) CMO Sells 411 Shares of Stock
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CMO David Shapiro sold 411 shares of the firm’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $153.34, for a total transaction of $63,022.74. Following the transaction, the chief marketing officer now owns 44,272 shares in the company, valued at $6,788,668.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
David Shapiro also recently made the following trade(s):
- On Monday, October 3rd, David Shapiro sold 1,513 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $163.08, for a total transaction of $246,740.04.
- On Monday, September 26th, David Shapiro sold 3,545 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $165.08, for a total transaction of $585,208.60.
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded down 4.67% on Wednesday, reaching $144.75. 477,345 shares of the company traded hands. The company’s market capitalization is $3.58 billion. The firm has a 50-day moving average of $156.21 and a 200-day moving average of $151.20. Intercept Pharmaceuticals Inc. has a 52-week low of $89.76 and a 52-week high of $217.99.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/insider-selling-intercept-pharmaceuticals-inc-icpt-cmo-sells-411-shares-of-stock.html
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The firm earned $5.52 million during the quarter, compared to the consensus estimate of $1.72 million. During the same quarter in the previous year, the company posted ($1.99) EPS. The business’s revenue for the quarter was up 1140.4% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 15th. Wedbush reiterated an “outperform” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, June 24th. Cantor Fitzgerald assumed coverage on shares of Intercept Pharmaceuticals in a research report on Wednesday, July 6th. They issued a “sell” rating and a $58.00 price objective on the stock. Laidlaw lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and lowered their price objective for the company from $345.00 to $105.00 in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Five investment analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $177.67.
A number of institutional investors have recently modified their holdings of the stock. CENTRAL TRUST Co acquired a new position in shares of Intercept Pharmaceuticals during the second quarter valued at about $107,000. Legal & General Group Plc boosted its stake in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 38 shares during the period. Pacer Advisors Inc. purchased a new stake in Intercept Pharmaceuticals during the second quarter valued at approximately $180,000. Finally, IBM Retirement Fund boosted its stake in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 58 shares during the period. Hedge funds and other institutional investors own 81.86% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.